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Abstract
Unfractionated heparin and low molecular weight heparin are the most commonly used
antithrombotic and thromboprophylactic agents in hospital practice. Extended out-of-hospital
treatment is inconvenient in that these agents must be administered parenterally. Current research
is directed at development of a safe and effective oral antithrombotic agent as an alternative for the
effective, yet difficult to use vitamin K antagonists. A novel drug delivery technology that facilitates
transport of drugs across the gastrointestinal epithelium has been harnessed to develop an oral
dosage form of unfractionated heparin. Combining unfractionated heparin with the carrier
molecule, sodium N-(8 [2-hydroxybenzoyl]amino) caprylate, or SNAC has markedly increased the
gastrointestinal absorption of this drug. Preclinical and clinical studies to-date suggests that oral
heparin-SNAC can confer a clinical efficacious effect; further confirmation is sought in planned
clinical trials.
Introduction
The current use of anticoagulants is extensive and it is esti-
mated that 0.7% of the population in the Western world
receive these drugs [1]. Broader indications for anticoagu-
lants and their increased use in the outpatient settings as
well as for long-term dosing has stimulated renewed inter-
est in developing oral anticoagulant and antithrombotic
agents. At present, the cornerstone of oral anticoagulants
are the vitamin K antagonists, of which the coumarin
derivative warfarin, (Coumadin) is the most widely used.
It has been used clinically for more than 50 years, and has
consistently demonstrated that adequate dosing virtually
eliminates recurrent venous thrombosis [2,3]. Neverthe-
less, warfarin has serious drawbacks that require steady
vigilance on the part of clinicians. These drawbacks
include significant drug-drug and food-drug interactions,
a slow onset and offset of effect, and a narrow therapeutic
index. Because of the inherent variability in response over
time and the consequently unpredictable pharmacody-
namics of the drug, frequent monitoring is necessary, an
inconvenience for the large number of patients who take
it chronically. Even with optimal warfarin monitoring in
patients with atrial fibrillation (AF), therapeutic anticoag-
ulation is achieved only half the time [4,5]. Because of
this, it is estimated that at least half the patients with non-
valvular AF who are eligible for warfarin therapy do not
receive it [6,7]. A forthcoming oral direct thrombin inhib-
itor, ximalegatran, was anticipated as a replacement for
warfarin, and study results were promising [8]. However,
concerns with regard to hepatotoxicity with long term use
have been raised [9].
A medical need still remains for a safe and effective oral
anticoagulant that is easier than warfarin for physicians
and patients to use on a long-term basis. In response to
this unmet need a novel oral drug delivery technology that
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enables poorly absorbed molecules to be absorbed
through the gastrointestinal tract was harnessed to devise
an oral form of unfractionated heparin (UFH) [10,11].
Theoretically an oral form of heparin or low molecular
weight heparin (LMWH) administered at a fixed dose,
twice or thrice daily, free of the need for frequent coagula-
tion monitoring or dose adjustments, and with a low
potential of drug-drug and food-drug interactions would
embody the desirable anticoagulant profile for long- term
oral use.
Heparin was discovered more than 80 years ago by a med-
ical student, Jay McLean who found that an extract of dog
liver prolonged the time required for plasma to clot ex vivo
[12]. It has been in clinical use for over 50 years and has
withstood the test of time in terms of both efficacy and
safety. Heparin remains one of the most important antico-
agulant drugs in current clinical use and is the drug of
choice when rapid effect is desired such as in the intensive
care setting, during surgery and for patients with renal fail-
ure. Over the past few decade LMWH preparations, which
are fragments of UFH produced by controlled enzymatic
or chemical depolymerization have risen in popularity.
LMWHs have a more predictable pharmacokinetic profile
than UFH can be administered by subcutaneous injection
(s.c.) once or twice daily and do not require laboratory
monitoring. This simplified regimen with LMWHs has
widened the range of their clinical applications and paved
the way for LMWHs to supersede UFH for most indica-
tions that necessitate out-patient and long-term treat-
ment. A major disadvantage of both UFH and LMWH
therapy lies in the fact that the size and charge of these
molecules make (.)parenteral administration a necessity.
The combination of UFH with a delivery agent, the basis
of the newly advanced drug delivery technology
employed, achieves heparin absorption when adminis-
tered orally, in amounts adequate for therapeutic purpose
and is currently in clinical trials [13-15]. Presented is a sta-
tus review of oral UFH including a brief description of the
technology employed and the results of clinical studies
thus far conducted with oral UFH.
The technology
For a drug to be absorbed from the gastrointestinal tract
and retain its efficacy, it must withstand the harsh chemi-
cal and biological milieu within the gastrointestinal tract.
In addition, to be absorbed it must have certain specific
physicochemical properties. Among these are a suitable
molecular weight (typically below 500–1000 daltons),
pKa (a measure of the degree of acidity or basisity), degree
of lipophilicity (log D) as well as proper solubility. Most
drugs are either weak acids or weak bases, and under nor-
mal conditions only the nonionized fraction (the most
lipophilic) crosses biological membranes, except where
active transport is involved. The new technology advanced
to overcome these limitations is based on carrier mole-
cules, which are comprised of small organic compounds
(200–400 Da). These carriers interact with the drug mole-
cules to create a weak, non-covalent association, the drug
remaining chemically unmodified [16-18]. The carriers
possess hydrophobic moieties that on association with
the drug molecules create a more lipophilic drug/carrier
complex, enabling transport across the epithelial mem-
brane [19-21]. Because of the weak association between
carrier and drug, the interaction is reversible, and occurs
spontaneously by simple dilution on entering the blood
circulation (Figure 1). Studies have shown that the carriers
enable the systemic absorption of the drug via transcellu-
lar absorption, a common drug absorption pathway,
without compromising the integrity of the intestinal epi-
thelium [17,22-24].
The carrier selected to develop oral forms of heparin is
sodium  N-(8 [2-hydroxybenzoyl]amino) caprylate, or
SNAC [10,11]. Heparin plasma levels attained with oral
heparin-SNAC (aPTT, anti-factor Xa assay) reached the
therapeutic range in humans, and were found to be effec-
tive in reducing the incidence of DVT in animal models of
venous thrombosis [13,14,25,26].
Heparin and its indications
In preclinical developmental studies, the carrier-based
technology was able to deliver orally both UFH and
LMWH [27-29]. A number of factors were considered in
the deliberation to advance UFH as the first oral heparin
Schematic depiction of drug delivery technology Figure 1
Schematic depiction of drug delivery technology. Car-
rier molecule (delivery agent) associates with drug molecule 
to create a transportable complex (lipophilic). Because of the 
weak association, carrier and drug dissociate by simple dilu-
tion on entering the blood circulation.
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candidate, not the least of which was the fact that the
LMWHs are currently still proprietary products.
Heparin, a naturally occurring glycosaminoglycan, in
addition to its anticoagulant effect is also implicated in an
ever growing number of physiological and pathological
processes such as inflammation, immune cell migration,
tumor cell metastasis, and smooth muscle cell (SMC) pro-
liferation among others [30-36]
The drug has a relatively rapid clearance, ranging from 30
minutes to 2.5 hours, depending on the dose, which
allows for relatively easy and frequent adjustments of
therapeutic level. Heparin dose can be readily measured
and monitored by a point-of-care assay using the activated
partial thromboplastin time (aPTT) [37,38]. On starting
heparin there is no initial hypercoagulable state or transi-
tion phase, and the anticoagulant effect can be reversed
with protamine if needed. Heparin is cleared and
degraded primarily by the reticuloendothelial system and
therefore is the drug of choice when full therapeutic anti-
coagulation therapy is required in patients with severe
renal failure [39].
An important activity of heparin and LMWHs is the
release of tissue factor pathway inhibitor (TFPI) from
endothelial cells [40]. Release of TFPI appears to be
related to the heparin chain length (MW) and degree of
sulfation, which are highest in UFH. As the chain length
shortens, the release of TFPI decreases [41-43]. Over-
expression of tissue factor, in addition to its procoagulant
effect, is also implicated in the pathophysiology of sepsis,
acute lung injury, disseminated intravascular clotting ang-
iogenesis and cancer [44-47]. Incidentally, the long half-
life of TFPI is also believed to account for the prolonged
protection from thrombosis conferred by heparins, rather
than by the mere activation of anti-factor Xa and anti-fac-
tor IIa, which have a relatively short plasma half-life.
LMWHs have largely supplanted UFH in the clinic
because of their more predictable pharmacokinetics and
essentially a safety profile comparable to that of UFH [48-
58]. After subcutaneous injection, LMWHs achieve a
higher bioavailability and a longer half-life (roughly 4
hours), allowing for a sustained effect with once or twice
daily fixed or weight-adjusted dosages and monitoring of
anticoagulant levels is usually not required.
It is common to assess clinical efficacy of novel anticoag-
ulants in DVT prophylaxis studies in high risk surgical
patients such as those after total hip replacement surgery.
The reason being that the prevalence of the DVT in these
patients is high and the duration of prophylaxis (postop-
erative treatment) is relatively short. Nevertheless, the
intended clinical indications for anticoagulant drugs, with
a few examples of which will be enumerated below, are
generally aimed at a broader patient population.
Oral heparin will be a particularly appropriate anticoagu-
lant for indications that require prophylaxis or treatment
for extended periods, months or indefinitely [59].
Extended prophylaxis is indicated as an example in situa-
tions such as when thrombosis is idiopathic or associated
with a continuing risk factor which cannot be identified
and eliminated, [60,61]. Indefinite anticoagulant therapy
is generally indicated in AF patients and in patients with
prosthetic heart valves, in patients with idiopathic recur-
rent proximal vein thrombosis, thrombosis complicating
malignancy, and in patients with homozygous factor V
Leidengenotype, the antiphospholipid antibody syn-
drome, or deficiencies of antithrombin III, protein C, or
protein S [62-64].
Anticoagulation in women of gestational age with pros-
pects of pregnancy requiring anticoagulation pose an
especially complex situation where oral heparin may have
an important role. Anticoagulant therapy during preg-
nancy is indicated for prevention and treatment of DVT,
for the prevention of and treatment of systemic embolism
in patients with mechanical heart valves and for the pre-
vention of pregnancy complications in women with
antiphospholipid antibodies or other thrombophilia and
previous pregnancy complications [65,66]. Coumarin
derivatives cross the placenta and can produce a character-
istic embryopathy with first-trimester exposure and, less
commonly, central nervous system abnormalities and
fetal bleeding with exposure after the first trimester [67].
For this reason, it has been recommended that warfarin
therapy be avoided during the first trimester of pregnancy
and, except in special circumstances, avoided entirely
throughout pregnancy. Neither UFH nor LMWH cross the
placenta and therefore these agents are safe in pregnancy.
Clinical and formulation development of oral heparin
The objectives of the initial clinical studies with oral
heparin-SNAC were to demonstrate a) the safety and tol-
erability of unformulated solutions of heparin/SNAC
combination b) that heparin without SNAC administered
orally is not absorbed, c) that SNAC by itself has no effects
on coagulation and d) to establish the minimal dose of
oral heparin required to have a pharmacological effect
when combined with maximal safe dose of SNAC. A sin-
gle dose of 30,000 USP Heparin Units or SNAC alone at
doses ranging from 1.4 to 10.5 g were administered orally.
Measurements of anticoagulation (aPTT, TFPI and anti-
Factors IIa and Xa levels) did not change following admin-
istration of either Heparin alone or SNAC alone. In a sub-
sequent study, an unformulated solution of SNAC (10.5
g) in combination with 10,000, 20,000 or 30,000 USP
heparin units were administered orally. Elevated aPTT,Thrombosis Journal 2006, 4:6 http://www.thrombosisjournal.com/content/4/1/6
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anti-Factors IIa and Xa levels were observed following oral
administration of 20,000 Units and 30,000 Units in com-
bination with 10.5 g of SNAC, demonstrating that SNAC
facilitates the absorption of heparin when administered as
heparin/SNAC solution in human subjects [13].
A taste-masked SNAC/Heparin oral solution formulation
was developed and evaluated at a fixed dose (2.25 g) of
SNAC in combination with escalating doses (30,000,
60,000, 90,000 and 150,000 Units) of heparin. Following
oral administration the subjects exhibited dose-depend-
ent prolongations in mean aPTT and anti-Factor Xa as
shown in Figure 2. Safety, tolerability and pharmacokinet-
ics of the taste-masked formulation were further evaluated
in a study comprising 12 healthy adults (age 18–59) and
12 healthy elderly (≥ 60 years old) volunteers. An addi-
tional objective was to compare the disposition (Emax,
AUEC0–8) of oral heparin/SNAC relative to s.c. injection
of 5000 Units heparin (Heparin Sodium Injection, USP;
Wyeth-Ayerst, Philadelphia, PA, USA). In this open-label
study, subjects received 15 mL of formulated, taste-
masked, oral heparin/SNAC solution (90 000 Units/2.25
g) every 8 hr, either 1 hour before or 2 hours after meals,
for a total of 16 doses over 6 days. The study showed that
a larger increase in aPTT occurred after oral heparin/SNAC
than s.c. UFH. A trend toward greater maximal increase
above baseline (Emax) and area under the effect curve
(AUEC) for aPTT and anti-FXa was observed in elderly
compared to younger subjects which was consistent with
a lower (9 kg) mean body weight. The half disappearance
time (t  1/2) was the same in adult and elderly subjects
when measured by aPTT, but there was a trend towards
prolonged anti-FXa effect in elderly subjects (0.5 vs. 0.38
hours on day 1 and 0.62 vs. 0.38 hours on day 6). There
was no significant difference in t1/2 between the last and
first doses.
In a phase II clinical trial 123 patients undergoing total
hip replacement were randomized to receive either oral
heparin/SNAC (1.5 g SNAC/60.000 units UFH or 2.25 g
SNAC/90.000 units UFH) as a taste masked oral solution
or 5000 Units UFH s.c every 8 hours. Patients received
study medication for 5 days and were observed for 35 days
following surgery. Efficacy assessment was based on day 5
bilateral full leg venous ultrasound and patients were fol-
lowed for symptomatic VTE events for 35 days. The study
revealed that major bleeding events (overall 3.3%) and
VTE (overall 4.9%) were not different in either of the two
dosages of oral heparin/SNAC or the s.c. heparin group.
This study provided the thrust for applying the tested reg-
imens of heparin/SNAC in a Phase III efficacy study.
An international, multi-center phase III thromboprophy-
laxis trial in 2264 patients with the objective to compare
safety and efficacy of two oral doses of UFH to a standard
subcutaneous LMWH regimen (PROTECT trial) in
patients undergoing elective hip surgery was conducted.
The clinical trial was randomized, double-blind (double-
dummy: placebo oral or injection). Oral heparin prophy-
laxis was initiated 4–6 hours postoperatively and contin-
ued through the whole evaluation period (27–30 days),
while enoxaparin was initiated 12–24 hours postopera-
tively and was administered for 10 days followed by pla-
cebo until the final evaluation. Oral heparin/SNAC
solution, low dose 60,000 IU/1.5 g SNAC (ldSNAC) and
high dose 90,000 IU/2.25 g SNAC (hdSNAC) were
administered trice daily. Subcutaneous LMWH (enoxa-
parin, Aventis Pharam, Bridgewater, NJ, USA) 30 mg twice
daily for 10 days was started 12–24 hours postoperatively
and followed by an identical subcutaneous placebo regi-
ment (double dummy) for up to a total of 27 – 30 days.
The primary end point was to demonstrate superiority of
oral heparin over s.c enoxaparin in reducing the DVT rate
as detected by bilateral ascending contrast venography at
day 27–30. For each treatment group 743 patients were
required to obtain 90% power for analysis of the deep-
vein thrombosis (DVT) rates (type I error of 0.025) assum-
ing an interpretable venogram rate of 65%. Baseline char-
acteristics on entry were comparable among the three
groups. The rationale for choosing superiority was based
on the fact that a procoagulant state persists for at least 4
weeks after THR and the vast majority of DVTs occur after
hospital discharge, between days 7 and 21 [68]. It has
been theorized that prolonged prophylaxis with an equiv-
alent efficacious drug to enoxaparin, such as oral heparin,
would confer superiority of anticoagulant effect over the
30 day study duration. Interpretable venogram was
obtained in 64% of patients and included a total of 752,
767, and 745 patients who were randomized to the
Anti-Factor Xa levels Figure 2
Anti-Factor Xa levels. Blood levels of Anti-Factor Xa after 
oral administration of heparin/SNAC in solution to healthy 
male volunteers (mean ± SEM). A dose response was 
observed. Heparin alone was not absorbed.
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ldSNAC, hdSNAC and LMWH/placebo groups respec-
tively. Fewer proximal and total DVT's and pulmonary
embolisms were observed in patients treated with enoxa-
parin (117 of 449, 26.1%) and high dose heparin-SNAC
(137 of 461, 29.7%) as compared to low dose heparin-
SNAC (155 of 488, 31.8%) treated patients (the absolute
differences and 95% CI for ldSNAC and hdSNAC com-
pared with LMWH were: 5.7% [0.1% to 11.7% CI] and
3.7% [-1.9% to 9.7% CI]). Proximal DVT or PE occurred
in 90 of 485 patients (18.6%) on ldSNAC, 64 of 465
patients (13.8%) on hdSNAC and 57 of 450 patients
(12.7%) treated with s.c. LMWH (p = 0.013 comparing
ldSNAC to s.c. LMWH and p = 0.045 comparing hdSNAC
to ldSNAC) [69]. In terms of safety, the incidence of
major/minor bleeding was 0%/1.9% of 728 low dose
heparin/SNAC patients, 0.7 %/2.0% of 736 high-dose
SNAC/heparin patients, and 0.4%/1.5% of 716 enoxa-
parin patients. The incidence of PE was very low and not
different for all three treatment groups (0.2% – 0.8%).
Wound hematomas occurred in 14 (1.9%) of ldSNAC
treated patients, 17 (2.3%) of hdSNAC treated patients,
and 21 (2.9%) of the s.c. LMWH group, with "compli-
cated" hematomas in 3 (0.4%), 7 (1.0%), and 6 (0.8%) of
patients treated with ldSNAC, hdSNAC and s.c. LMWH,
respectively. Two patients who suffered thombocytopenia
received prophylaxis with intravenous UFH. This study
did not meet its primary end point, likely due to a subop-
timal dosage form and a poorly tasting liquid formula-
tion; however, it provided proof of concept that heparin
delivered by the oral route had potent antithrombotic
activity. The study was the first to document in a large
patient population that oral heparin can reduce the fre-
quency of postoperative VTE with low frequency of bleed-
ing complications in patients undergoing total hip
replacement surgery [15].
A posthoc analysis was undertaken in all patients (a total
of 299) enrolled for the study in the US, Canada and Aus-
tralia, which were sites where compliance and adherence
to study protocol could be confirmed. In this analysis a
statistical significant reduction in the incidence of DVT
was observed in patients assigned to high dose oral
heparin compared to the s.c. LMWH group (Table 1). We
recognize the limitations of a posthoc analysis approach;
nonetheless, the observation of an improved outcome
with oral heparin as compared to parentral s.c. LMWH
provides impetus for further studies of this product.
The results from the PROTECT trial made clear the need to
overcome the adverse taste of the oral heparin formula-
tion and attain a more patient-friendly formulation of
heparin/SNAC with the focus being a solid dosage form.
Several solid dosage forms were evaluated and a solid oral
dosage form that achieved plasma anti-factor Xa levels
(Figure 3), comparable to those for the oral solution for-
mulation in healthy volunteers was successfully devel-
oped [70]. The clinical development of oral heparin will
continue with the evaluation of an optimized solid dos-
age form and plans are currently underway to evaluate the
new heparin/SNAC solid dosage form in a thrombo-
prophylaxis study.
Conclusion
Although UFH has been in use for decades, attempts to
convert either UFH or LMWH to an oral dosage form have
been discouraging. Recent studies have shown that the
addition of a carrier molecule such as SNAC can facilitate
the enteric absorption of both UFH and LMWH and reach
levels that are adequate for both prevention and treatment
of venous thromboembolic disease in animals and
humans. In a phase III randomized clinical trial, it was
demonstrated that oral heparin-SNAC reduced the inci-
dence of proximal venous thrombosis in patients under-
going hip replacement surgery in a dose-dependent
fashion compared with standard LMWH given subcutane-
ously. This proof of concept demonstration warrants fur-
ther studies with oral UFH and LMWH, particularly in a
solid dosage form. The oral route still remains the safest,
most convenient, most economical and the one which
fosters the greatest patient compliance and adherence, vir-
tues that are likely to translate to better health care.
As with all new therapeutic agents there is always concern
of new and unexpected toxicity being uncovered over time
and with wider use. UFH and LMWH have been in use for
decades. Although they are associated with undesirable
effects including bleeding, HIT and osteoporosis, these are
well known, recognized, managed and it is unlikely that
new side effects will be uncovered with further use of
these agents.
Table 1: PROTECT Trial, post-hoc analysis of ITTIV population
ITTIV population N = 299 
(includes all patients from USA, 
Canada/Australia)
Low dose oral-heparin (60,000 IU/
1.5 g SNAC) 30 days)
High dose oral-heparin (90,000 IU/
2.25 g SNAC) 30 days
Injectable LOVENOX ® 30 mg s.c 
b.i.d.)10-day followed by placebo 
(to day 30)
Total DVT rate 27% 18% 28%
Relative Risk Reduction 4% 55%Thrombosis Journal 2006, 4:6 http://www.thrombosisjournal.com/content/4/1/6
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